Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Vaccines in Asymptomatic High-Risk CLL/SLL
NCT02518555Phase 2Completed
- Start
- Jan 2016
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms). Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02518555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02518555.